Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report

• Principais autores: Toshihisa Kimura MD, PhD (Autor), Tamotsu Togawa MD (Autor), Kenji Onishi MD, PhD (Autor), Atsushi Iida MD, PhD (Autor), Yasunori Sato MD, PhD (Autor), Takanori Goi MD, PhD (Autor)
• Formato: Livro
• Publicado em: SAGE Publishing, 2020-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Although most patients with advanced GISTs benefit from imatinib mesylate (IM) as standard targeted therapy, the optimal duration of adjuvant IM for GIST patients with high risk of recurr...